COVID-19-related myocarditis and cholinergic anti-inflammatory pathways
| dc.creator | Liu, Weike | |
| dc.creator | Liu, Zhendong | |
| dc.creator | Li, Yue-Chun | |
| dc.date.accessioned | 2020-12-09T20:58:05Z | |
| dc.date.available | 2020-12-09T20:58:05Z | |
| dc.date.created | 2020 | |
| dc.description.abstract | Coronavirus disease (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), is currently in a pandemic outbreak and has become a global health issue. In addition to primarily involving the respiratory system, myocarditis is considered an important and fatal lesion in patients with COVID-19. However, effective therapeutic methods are currently lacking. The cholinergic anti-inflammatory pathway (CAP) has been demonstrated to suppress pro-inflammatory cytokine production and control inflammation in sepsis and other medical conditions. Therefore, the CAP may be a potential and effective therapeutic method for COVID-19-related myocarditis. This article reviews the relationship between COVID-19-related myocarditis and the CAP and discusses the CAP as a potential therapeutic modality in the treatment of COVID-19-related myocarditis. | spa |
| dc.format.extent | 19 páginas | spa |
| dc.format.mimetype | application/pdf | spa |
| dc.identifier.doi | https://doi.org/10.1016/j.hjc.2020.12.004 | spa |
| dc.identifier.issn | 1109-9666 | spa |
| dc.identifier.other | https://doi.org/10.1016/j.hjc.2020.12.004 | spa |
| dc.identifier.uri | https://hdl.handle.net/20.500.12010/16432 | |
| dc.language.iso | eng | spa |
| dc.publisher | Hellenic Journal of Cardiology | spa |
| dc.rights.accessrights | info:eu-repo/semantics/openAccess | spa |
| dc.rights.local | Abierto (Texto Completo) | spa |
| dc.source | reponame:Expeditio Repositorio Institucional UJTL | spa |
| dc.source | instname:Universidad de Bogotá Jorge Tadeo Lozano | spa |
| dc.subject | Severe acute respiratory syndrome coronavirus-2 | spa |
| dc.subject | Myocarditis | spa |
| dc.subject | Cholinergic anti-inflammatory pathway | spa |
| dc.subject.lemb | Síndrome respiratorio agudo grave | spa |
| dc.subject.lemb | COVID-19 | spa |
| dc.subject.lemb | SARS-CoV-2 | spa |
| dc.subject.lemb | Coronavirus | spa |
| dc.title | COVID-19-related myocarditis and cholinergic anti-inflammatory pathways | spa |
| dc.type.coar | http://purl.org/coar/resource_type/c_2df8fbb1 | spa |
| dc.type.hasversion | info:eu-repo/semantics/acceptedVersion | spa |
| dc.type.local | Artículo | spa |
Archivos
Bloque de licencias
1 - 1 de 1
Cargando...
- Nombre:
- license.txt
- Tamaño:
- 2.87 KB
- Formato:
- Item-specific license agreed upon to submission
- Descripción: